Mahamaya Lifesciences IPO is a book build issue of ₹70.44 crores. The issue is a combination of fresh issue of 0.56 crore shares aggregating to ₹64.28 crores and offer for sale of 0.05 crore shares aggregating to ₹6.16 crores.
Mahamaya Lifesciences IPO opens for subscription on Nov 11, 2025 and closes on Nov 13, 2025. The allotment for the Mahamaya Lifesciences IPO is expected to be finalized on Nov 14, 2025. Mahamaya Lifesciences IPO will list on BSE SME with a tentative listing date fixed as Nov 18, 2025.
Mahamaya Lifesciences IPO price band is set at ₹108.00 to ₹114.00 per share . The lot size for an application is 1,200. The minimum amount of investment required by an individual investor (retail) is ₹2,73,600.00 (2,400 shares) (based on upper price). The minimum lot size investment for HNI is 3 lots (3,600 shares), amounting to ₹4,10,400.
Oneview Corporate Advisors Pvt.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Mansi Share & Stock Broking Pvt.Ltd..
Refer to Mahamaya Lifesciences IPO RHP for detailed Information.
| IPO Date | November 11, 2025 to November 13, 2025 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | ₹108 to ₹114 per share |
| Lot Size | 1,200 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 61,78,800 shares (aggregating up to ₹70.44 Cr) |
| Reserved for Market Maker | 3,09,600 shares Mansi Share & Stock Broking Pvt.Ltd. (aggregating up to ₹3.53 Cr) |
| Fresh Issue (Ex Market Maker) | 53,29,200 shares (aggregating up to ₹60.75 Cr) |
| Offer for Sale | 5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr) |
| Net Offered to Public | 58,69,200 shares (aggregating up to ₹66.91 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 1,77,66,200 shares |
| Share Holding Post Issue | 2,34,05,000 shares |
Mahamaya Lifesciences IPO offers total 61,78,800 shares. Out of which 29,28,000 (47.39%) allocated to QIB, 11,76,000 (19.03%) allocated to QIB (Ex- Anchor), 8,82,000 (14.27%) allocated to NII 20,59,200 (33.33%) allocated to RII and 17,52,000 (28.36%) allocated to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Market Maker Shares Offered | 3,09,600 (5.01%) |
| QIB Shares Offered | 29,28,000 (47.39%) |
| − Anchor Investor Shares Offered | 17,52,000 (28.36%) |
| − QIB (Ex. Anchor) Shares Offered | 11,76,000 (19.03%) |
| NII (HNI) Shares Offered | 8,82,000 (14.27%) |
| − bNII > ₹10L | 5,88,000 (9.52%) |
| − sNII < ₹10L | 2,94,000 (4.76%) |
| Retail Shares Offered | 20,59,200 (33.33%) |
| Total Shares Offered | 61,78,800 (100.00%) |
Mahamaya Lifesciences IPO raises ₹19.97 crore from anchor investors. Mahamaya Lifesciences IPO Anchor bid date is November 10, 2025.
| Bid Date | November 10, 2025 |
| Shares Offered | 17,52,000 |
| Anchor Portion Size (In Cr.) | 19.97 |
| Anchor lock-in period end date for 50% shares (30 Days) | December 14, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | February 12, 2026 |
Mahamaya Lifesciences IPO opens on November 11, 2025, and closes on November 13, 2025.
| IPO Open Date | Tue, Nov 11, 2025 |
| IPO Close Date | Thu, Nov 13, 2025 |
| Tentative Allotment | Fri, Nov 14, 2025 |
| Initiation of Refunds | Mon, Nov 17, 2025 |
| Credit of Shares to Demat | Mon, Nov 17, 2025 |
| Tentative Listing Date | Tue, Nov 18, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Thu, Nov 13, 2025 |
Investors can bid for a minimum of 2,400 shares and in multiples of 1,200 shares thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,400 | ₹2,73,600 |
| Individual investors (Retail) (Max) | 2 | 2,400 | ₹2,73,600 |
| S-HNI (Min) | 3 | 3,600 | ₹4,10,400 |
| S-HNI (Max) | 7 | 8,400 | ₹9,57,600 |
| B-HNI (Min) | 8 | 9,600 | ₹10,94,400 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.
The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).
The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).
The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.
Product Portfolio:
Competitive Strengths:
Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Total Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit After Tax | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves and Surplus | 35.73 | 31.66 | 23.41 | 18.19 |
| Total Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
| Amount in ₹ Crore | ||||
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| ROE | 34.94% |
| ROCE | 23.15% |
| Debt/Equity | 1.08 |
| RoNW | 26.19% |
| PAT Margin | 4.84% |
| EBITDA Margin | 9.22% |
| Price to Book Value | 9.40 |
| Market Capitalization | 266.82 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 7.29 | 7.01 |
| P/E (x) | 15.65 | 16.25 |
The Company Mahamaya Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Purchase of Equipment for existing Formulation plant | 3.75 |
| 2 | Funding capital expenditure towards setting up of a new technical manufacturing plant | 29.42 |
| 3 | Construction of Warehouse Building and Purchase of Machinery | 2.53 |
| 4 | Funding working capital requirement of our Company | 18.00 |
| 5 | General Corporate purposes |
[Dilip Davda] MLL started as importer/trader of critical and specialized pesticide formulations has now started manufacturing the same. The company posted growth in its top and bottom lines for the reported periods. Boosted top and bottom lines from FY25 onwards raise eyebrows and concern over its sustainability. Based on its recent financial data, the issue appears fully priced. Investors may park funds for medium to long term. Read detail review...
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: mahamaya.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Mahamaya Lifesciences IPO is a SME IPO of 61,78,800 equity shares of the face value of ₹10 aggregating up to ₹70.44 Crores. The issue is priced at . The minimum order quantity is 1200.
The IPO opens on November 11, 2025, and closes on November 13, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Mahamaya Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Mahamaya Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Mahamaya Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Mahamaya Lifesciences IPO opens on November 11, 2025 and closes on November 13, 2025.
Mahamaya Lifesciences IPO lot size is 1200, and the minimum amount required for application is ₹2,73,600, with 2 lots being the minimum application size.
You can apply in Mahamaya Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Mahamaya Lifesciences IPO will be done on Friday, November 14, 2025, and the allotted shares will be credited to your demat account by Monday, November 17, 2025. Check the Mahamaya Lifesciences IPO allotment status.
The Mahamaya Lifesciences IPO listing date is not yet announced. The tentative date of Mahamaya Lifesciences IPO listing is Tuesday, November 18, 2025.
Useful Articles
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
RHP
